Trials / Completed
CompletedNCT04918407
Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation
Effects of Empagliflozin in Reducing Oxidative Stress of Diabetic Recipients After Kidney Transplantation
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Shahid Beheshti University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effect of empagliflozin on oxidative stress in patients with type 2 diabetes after kidney transplantation. The association is examined by comparing the difference in oxidative modifications before and after 90 days treatment with 25 mg empagliflozin plus insulin compared to insulin treatment. The study is randomised and double-blinded. Each treatment group consists of 20 patients. Oxidative stress markers are measured by serum level of superoxide dismutase activity ,lipid peroxidation assay kit, glutathione assay, glutathione peroxidase activity , total antioxidant capacity assay oxidant status , carbonyl content assay and bca protein assay . . A student t-test will be performed to compare adding empagliflozin . The results will be published in a peer-review journal.
Detailed description
With the purpose of studying the antioxidant activity of empagloflozin 25mg will add on insulin in 20 patients after kidney transplant and will compare with 20 diabetic recipient of kidney transplant on insulin therapy alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin 25 MG | 25 mg |
| DRUG | Insulin | Insulin |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2025-07-05
- Completion
- 2025-08-05
- First posted
- 2021-06-08
- Last updated
- 2025-09-08
Locations
2 sites across 1 country: Iran
Source: ClinicalTrials.gov record NCT04918407. Inclusion in this directory is not an endorsement.